MP76-09 GROWTH HORMONE RELEASING PEPTIDE TREATMENT IN MEN INCREASES SERUM INSULIN-LIKE GROWTH FACTOR-1 LEVELS

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I1 Apr 2016MP76-09 GROWTH HORMONE RELEASING PEPTIDE TREATMENT IN MEN INCREASES SERUM INSULIN-LIKE GROWTH FACTOR-1 LEVELS John T. Sigalos, Andrew Allison, Alexander Pastuszak, Samuel J. Ohlander, Amin Herati, Mark C. Lindgren, and Larry I. Lipshultz John T. SigalosJohn T. Sigalos More articles by this author , Andrew AllisonAndrew Allison More articles by this author , Alexander PastuszakAlexander Pastuszak More articles by this author , Samuel J. OhlanderSamuel J. Ohlander More articles by this author , Amin HeratiAmin Herati More articles by this author , Mark C. LindgrenMark C. Lindgren More articles by this author , and Larry I. LipshultzLarry I. Lipshultz More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1860AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Stimulation of growth hormone (GH) secretion, rather than administration of exogenous GH, which is severely limited by FDA regulations, may afford a safer approach to obtaining the benefits of GH while avoiding the adverse effects associated with exogenous GH. Few studies have evaluated the effects of GH secretagogues on GH and insulin-like growth factor-1 (IGF-1) secretion in humans. These GH secretagogues include GH releasing peptides (GHRP) GHRP-2 and GHRP-6, and the GH releasing hormone (GHRH) analogue, sermorelin (SERM). IGF-1 serves as a surrogate marker for GH production. Here we present data evaluating the impact of GHRP/SERM therapy on IGF-1 levels. METHODS A retrospective review of medical records was performed for 105 men already on testosterone therapy seeking gains in lean body mass who were prescribed GHRP-6, GHRP-2, and SERM 3 times daily in a dose of 100 mcg of each peptide. Serum IGF-1 level were assessed in response to treatment. To gauge efficacy and compliance, study inclusion criteria included 1) evidence of drug use, assessed via frequency of prescription fills, 2) interval lab testing every 3-4 months, 3) a low-normal baseline IGF-1 (<200 ng/ml). After assessment, the 14 men who met inclusion criteria were evaluated. RESULTS Mean (SD) age within the cohort (n=14) was 33.2 (2.9) years, and baseline serum IGF-1 level was 159.5 (26.7) ng/ml. Mean (SD) duration of continuous GHRH/GHRP treatment was 134 (88) days. Post treatment IGF-1 level was 239 (54.6) ng/ml (p<0.0001). 4 of 11 men were co-administered an aromatase inhibitor and/or tamoxifen due to elevated estradiol (E2) levels and/or gynecomastia during treatment. Interestingly, decreasing E2 production or estrogen receptor blockade had a negative effect on IGF-1 production (Figure 1). CONCLUSIONS Combination therapy with GHRP-6, GHRP-2, and SERM increases serum IGF-1 levels. This effect is observed with strict compliance to 3 times daily dosing. Increases in serum IGF-1 while on treatment approached the upper limits of our laboratory reference range (250 ng/ml), but were inhibited by blocking estrogen action. Taken together, our results suggest that combination therapy with GHRP-6, GHRP-2, and SERM may be beneficial in wasting conditions. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1010 Advertisement Copyright & Permissions© 2016MetricsAuthor Information John T. Sigalos More articles by this author Andrew Allison More articles by this author Alexander Pastuszak More articles by this author Samuel J. Ohlander More articles by this author Amin Herati More articles by this author Mark C. Lindgren More articles by this author Larry I. Lipshultz More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...